Please assess the completion status of the following clinical trial:

Trial Title: Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented, aggressive and/or intermediate grade and high-grade B cell NHL, CD20 positive.~* Histologic subtypes include follicular large cell, diffuse small cleaved cell, diffuse mixed small and large cell, diffuse large cell, anaplastic large cell, and mantle cell lymphomas.~* NHL must have high-intermediate or high International Prognostic Index (standard IPI) score at diagnosis. Mantle cell NHL is eligible regardless of IPI score.~* Complete or partial response to first-line therapy.~* Treated CNS or meningeal disease, using radiation therapy and/or intrathecal chemotherapy, is allowed. Patients with meningeal disease must have cytologically negative CSF at time of study entry.~* Cumulative total doxorubicin: \<500 mg/m2~* Performance score 0-2~* Patients with a prior malignancy are eligible if they were treated with curative intent and have no evidence of active disease.~* Patients must not be pregnant or nursing.~* Informed Consent~Exclusion Criteria:~* pregnant or nursing

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).